Previous 10 | Next 10 |
home / stock / ctlt / ctlt articles
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials ...
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "...
The unprecedented demand for weight loss drugs, including Novo Nordisk A/S’s (NYSE:NVO) Wegovy and Eli Lilly And Co’s&nb...
The resilient U.S. stock market is on track to close the week on a positive note as futures pointed to a modestly higher open on Friday, with the s...
Novo Nordisk A/S (NYSE:NVO) has encountered manufacturing challenges and drug shortages for its diabetes and weight loss drugs due to unpreced...
MONSEY, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Catalent, Inc. (NYSE:CTLT) ("Ca...
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the...
On Monday, Catalent, Inc. (NYSE: CTLT) announced it will be acquired by Novo Holdings. Novo Holdings will acquire all outstanding shares of Catal...
News, Short Squeeze, Breakout and More Instantly...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Catalent, Inc. (NYSE: CTLT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 3.37% on the day to $56.66. Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologi...